Red blood cell distribution width as a novel prognostic marker after myocardial revascularization or cardiac valve surgery.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 04 2021
Historique:
received: 06 07 2020
accepted: 02 02 2021
entrez: 13 4 2021
pubmed: 14 4 2021
medline: 9 11 2021
Statut: epublish

Résumé

The red blood cell distribution width (RDW) measures the variability in the size of circulating erythrocytes. Previous studies suggested a powerful correlation between RDW obtained from a standard complete blood count and cardiovascular diseases in both primary and secondary cardiovascular prevention. The current study aimed to evaluate the prognostic role of RDW in patients undergoing cardiac rehabilitation after myocardial revascularization and/or cardiac valve surgery. The study included 1.031 patients with available RDW levels, prospectively followed for a mean of 4.5 ± 3.5 years. The mean age was 68 ± 12 years, the mean RDW was 14.7 ± 1.8%; 492 patients (48%) underwent cardiac rehabilitation after myocardial revascularization, 371 (36%) after cardiac valve surgery, 102 (10%) after valve-plus-coronary artery by-pass graft surgery, 66 (6%) for other indications. Kaplan-Meier analysis and Cox hazard analysis were used to associate RDW with mortality. Kaplan-Meier analysis demonstrated worse survival curves free from overall (log-rank p < 0.0001) and cardiovascular (log-rank p < 0.0001) mortality in the highest RDW tertile. Cox analysis showed RDW levels correlated significantly with the probability of overall (HR 1.26; 95% CI 1.19-1.32; p < 0.001) and cardiovascular (HR 1.31; 95% CI 1.23-1.40; p < 0.001) mortality. After multiple adjustments for cardiovascular risk factors, hemoglobin, hematocrit, C-reactive protein, microalbuminuria, atrial fibrillation, glomerular filtration rate,left ventricular ejection fraction and number of exercise training sessions attended, the increased risk of overall (HR 1.10; 95% CI 1.01-1.27; p = 0.039) and cardiovascular (HR 1.13; 95% CI 1.01-1.34; p = 0.036)mortality with increasing RDW values remained significant. The RDW represents an independent predictor of overall and cardiovascular mortality in secondary cardiovascular prevention patients undergoing cardiac rehabilitation.

Identifiants

pubmed: 33846483
doi: 10.1038/s41598-021-87075-4
pii: 10.1038/s41598-021-87075-4
pmc: PMC8041885
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7889

Références

Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2054-61
pubmed: 16037567
J Am Coll Cardiol. 2007 Jul 3;50(1):40-7
pubmed: 17601544
Microvasc Res. 2015 Mar;98:102-7
pubmed: 25660474
J Intern Med. 2014 Jan;275(1):84-92
pubmed: 24112470
Dis Markers. 2017;2017:7089493
pubmed: 29038615
N Engl J Med. 2003 Dec 11;349(24):2316-25
pubmed: 14668457
Int J Cardiol. 2013 Jul 1;166(3):664-71
pubmed: 22192286
Dig Dis Sci. 2008 Sep;53(9):2521-3
pubmed: 18259864
Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):440-6
pubmed: 12615689
J Cardiovasc Pharmacol. 2013 Oct;62(4):388-93
pubmed: 23921307
J Heart Valve Dis. 2017 Nov;26(6):714-720
pubmed: 30207123
J Intern Med. 2014 Aug;276(2):174-83
pubmed: 24471821
Am J Cardiol. 2015 Feb 1;115(3):328-33
pubmed: 25579885
Blood Press. 2012 Jun;21(3):177-81
pubmed: 22243409
Eur J Cardiothorac Surg. 2013 Jun;43(6):1165-9
pubmed: 23277431
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):697-705
pubmed: 16424350
J Thorac Dis. 2015 Oct;7(10):E402-11
pubmed: 26623117
Thromb Haemost. 2014 Feb;111(2):300-7
pubmed: 24173039
Circulation. 2008 Jan 15;117(2):163-168
pubmed: 18172029
Int Heart J. 2016 Sep 28;57(5):553-7
pubmed: 27581674
Med Glas (Zenica). 2016 Aug 1;13(2):75-81
pubmed: 27452327
BMC Cardiovasc Disord. 2019 Jul 24;19(1):175
pubmed: 31340761
Clin Hemorheol Microcirc. 2012;51(4):243-54
pubmed: 22277951
J Am Heart Assoc. 2014 Aug 18;3(4):
pubmed: 25134681
Thromb Res. 2014 Mar;133(3):334-9
pubmed: 24393657
Perfusion. 2005 Mar;20(2):83-90
pubmed: 15918445
J Cardiol. 2019 Sep;74(3):212-216
pubmed: 31060955
Am J Epidemiol. 2010 Jan 15;171(2):214-20
pubmed: 20008450
PLoS One. 2015 May 11;10(5):e0126272
pubmed: 25961836
Am Heart J. 2009 Jun;157(6):1057-63
pubmed: 19464417
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
PLoS One. 2015 May 07;10(5):e0124957
pubmed: 25950717
Adv Exp Med Biol. 2013;765:211-216
pubmed: 22879035
Eur J Prev Cardiol. 2017 Mar;24(4):357-364
pubmed: 27895211

Auteurs

Davide Lazzeroni (D)

IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy. davide.lazzeroni@gmail.com.
, Piazzale dei Servi, n°3, 43121, Parma, Italy. davide.lazzeroni@gmail.com.

Luca Moderato (L)

Guglielmo da Saliceto Hospital, Piacenza, Italy.

P L Marazzi (PL)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Carmen Pellegrino (C)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Elisa Musiari (E)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Paolo Castiglioni (P)

IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.

Umberto Camaiora (U)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Matteo Bini (M)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Simone Geroldi (S)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Lorenzo Brambilla (L)

IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.

Valerio Brambilla (V)

Fondazione Don Carlo Gnocchi, Parma, Italy.

Paolo Coruzzi (P)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH